Industry Coverage Report on Indian Pharmaceuticals Sector which encapsulates the structure, drivers, key trends, concentration and current scenario. Prepared by me in association with the Alpha Investment & Research Club, FMS Delhi.
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...BIS Research Inc.
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
This document provides an overview of research methodology for studying the Indian pharmaceutical market and the effect of healthcare products. The objectives are to understand the market contribution of healthcare products and evaluate consumers' and doctors' attitudes towards these products. Secondary research will gather data from company sources, while primary research will involve interviews with chemists, doctors, and consumers. The study aims to benefit researchers, the sponsoring organization, and colleagues by providing insights into opportunities in the domestic pharmaceutical market.
Immunotherapy Drugs Market PPT: Demand, Trends and Business Opportunities 202...IMARC Group
The global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 327.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.
More Info:- https://www.imarcgroup.com/immunotherapy-drugs-market
Analgesics Market Development, Trends, Demand and Forecast Till 2027IMARC Group
According to the latest report by IMARC Group, the global analgesics market reached a value of US$ 49.02 Billion in 2021. Analgesics refers to a class of drugs that help relieve pain without blocking nerve impulse conduction, affecting consciousness or altering sensory perception. They function by limiting the transmission of pain signals to the brain and interfering with its ability to interpret those signals. Derived from salicylic acid and phenacetin, some common analgesics include acetaminophen, aspirin, paracetamol, COX inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid drugs
Biomarkers: Discovery Techniques and Applications - A Global Market Overview ...MarketResearch.com
This document provides a summary of a market research report on biomarkers. It discusses biomarker discovery techniques like bioimaging, bioinformatics, and omics technologies. It also analyzes biomarker markets by therapeutic areas like cardiology, neurology, and oncology. The global biomarkers market was estimated to be $47 billion in 2013, with the US as the leading market. The market is projected to grow to $63.2 billion by 2020 with a compound annual growth rate of 18.8%. The 350-page report provides market data, profiles major companies, and lists biomarkers research organizations.
Industry Coverage Report on Indian Pharmaceuticals Sector which encapsulates the structure, drivers, key trends, concentration and current scenario. Prepared by me in association with the Alpha Investment & Research Club, FMS Delhi.
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...BIS Research Inc.
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
This document provides an overview of research methodology for studying the Indian pharmaceutical market and the effect of healthcare products. The objectives are to understand the market contribution of healthcare products and evaluate consumers' and doctors' attitudes towards these products. Secondary research will gather data from company sources, while primary research will involve interviews with chemists, doctors, and consumers. The study aims to benefit researchers, the sponsoring organization, and colleagues by providing insights into opportunities in the domestic pharmaceutical market.
Immunotherapy Drugs Market PPT: Demand, Trends and Business Opportunities 202...IMARC Group
The global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 327.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.
More Info:- https://www.imarcgroup.com/immunotherapy-drugs-market
Analgesics Market Development, Trends, Demand and Forecast Till 2027IMARC Group
According to the latest report by IMARC Group, the global analgesics market reached a value of US$ 49.02 Billion in 2021. Analgesics refers to a class of drugs that help relieve pain without blocking nerve impulse conduction, affecting consciousness or altering sensory perception. They function by limiting the transmission of pain signals to the brain and interfering with its ability to interpret those signals. Derived from salicylic acid and phenacetin, some common analgesics include acetaminophen, aspirin, paracetamol, COX inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid drugs
Biomarkers: Discovery Techniques and Applications - A Global Market Overview ...MarketResearch.com
This document provides a summary of a market research report on biomarkers. It discusses biomarker discovery techniques like bioimaging, bioinformatics, and omics technologies. It also analyzes biomarker markets by therapeutic areas like cardiology, neurology, and oncology. The global biomarkers market was estimated to be $47 billion in 2013, with the US as the leading market. The market is projected to grow to $63.2 billion by 2020 with a compound annual growth rate of 18.8%. The 350-page report provides market data, profiles major companies, and lists biomarkers research organizations.
Global Biotechnology Market is estimated to reach $726.8 billion by 2025; growing at a CAGR of 8.1% from 2017 to 2025. Biotechnology is the technology to upgrade or modify the whole part of biological system for human and industrial welfare. It is defined as the industrial application of living organisms and their biological processes such as microbiology, genetic engineering, biochemistry among others, so as to make best usage of the microorganisms for the benefit of mankind. Industrial biotechnology application has also steered some clear processes that produces less waste, less energy and water. It is also used in various industrial sectors such as pulp chemical, paper, textiles, minerals and metal industries, among others.
The global in-vitro diagnostics market size was valued at US$ 60,274.1 million in 2017, and is expected to exhibit a CAGR of 4.6% over the forecast period (2018–2026).
Regenerative Medicine Market PPT 2021: Size, Growth, Demand and Forecast till...IMARC Group
As per the latest report by IMARC Group,the global Regenerative medicine market size reached a strong growth in 2020.
Regenerative medicines refer to an interdisciplinary field that plays a vital role in tissue and organ transplants.
Biodefense Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by T...IMARC Group
According to the latest report by IMARC Group,the global biodefense market size reached US$ 12.7 Billion by 2020.
Biodefense includes the utilization of several medical and military measures that are taken to safeguard individuals against bioterrorism.
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...IMARC Group
The global Pompe disease treatment market size reached US$ 1.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.3 Billion by 2032, exhibiting a growth rate (CAGR) of 2.58% during 2024-2032.
More Info:- https://www.imarcgroup.com/pompe-disease-treatment-market
Corporate Wellness Market by Product Type, Distribution Channel, End User 202...IMARC Group
The global corporate wellness market size reached US$ 66.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 118.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/corporate-wellness-market
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032IMARC Group
The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/migraine-drugs-market
Empty Capsules Market by Product Type, Distribution Channel, End User 2023-2028IMARC Group
The global empty capsules market size reached US$ 2.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 7.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/empty-capsules-market
MarketResearchReports.com has announced the addition of “Forecast of Global Clinical Trial Supplies Consumption Market Report 2023” research report to their offering. See more at- http://mrr.cm/wWQ
This document summarizes a report on the global zoonotic disease treatment market. Zoonotic diseases are those spread between animals and humans. The market is driven by factors like population growth, urbanization, and increased consumption of animal proteins. However, lack of disease awareness, high research costs, and drug prices restrain the market. The market is expected to grow due to rising meat consumption and income levels in developing nations. North America currently dominates the market but Asia Pacific is expected to experience increased zoonotic disease prevalence due to poor sanitation. The report provides an overview, key drivers and restraints, regional analysis, and profiles major market players.
Addiction Treatment Market by Product Type, Distribution Channel, End User 20...IMARC Group
The global addiction treatment market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.76% during 2024-2032.
More Info:- https://www.imarcgroup.com/addiction-treatment-market
Pharmaceutical industry pestel analysisRahul Pagaria
The pharmaceutical industry in India is a rapidly growing sector that produces low-cost, high-quality drugs. It has a total market size of over $20 billion and has grown at around 12.5% annually over the past five years. Key players in the industry include Ranbaxy, Dr. Reddy's, Cipla, and Lupin. A PESTEL analysis identified political issues like price controls, social factors like an aging population and increased patient expectations, economic challenges from the global crisis, opportunities from new technologies, and an increasing focus on the environmental impact of the industry.
This document summarizes a report on the biostimulants market. It grew steadily from 2020 to 2027 with a compound annual growth rate expected to improve. Biostimulants are used in agriculture to enhance plant growth and are segmented by application into foliar, soil, and seed treatments. They are also segmented by crop type into row crops, fruits and vegetables, turfs and ornamentals, and other crop types. The document provides an overview of key players in the biostimulants market and requests a free PDF sample of the full report.
Human Insulin Market Growth, Demand and Challenges of the Key Industry Player...IMARC Group
The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
More Info:- https://www.imarcgroup.com/human-insulin-market
Sports Medicine Market Report in PPT: Top Companies, Trends and Future Detail...IMARC Group
Looking forward, the sports medicine market value is projected to reach a strong growth during the forecast period (2022-2027).
More info:- https://www.imarcgroup.com/sports-medicine-market
Cell Therapy Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global cell therapy market size reached US$ 11.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 32.1 Billion by 2028, exhibiting a growth rate (CAGR) of 17.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/cell-therapy-market
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
More Related Content
Similar to Global Precision Medicine Market 2018-2028
Global Biotechnology Market is estimated to reach $726.8 billion by 2025; growing at a CAGR of 8.1% from 2017 to 2025. Biotechnology is the technology to upgrade or modify the whole part of biological system for human and industrial welfare. It is defined as the industrial application of living organisms and their biological processes such as microbiology, genetic engineering, biochemistry among others, so as to make best usage of the microorganisms for the benefit of mankind. Industrial biotechnology application has also steered some clear processes that produces less waste, less energy and water. It is also used in various industrial sectors such as pulp chemical, paper, textiles, minerals and metal industries, among others.
The global in-vitro diagnostics market size was valued at US$ 60,274.1 million in 2017, and is expected to exhibit a CAGR of 4.6% over the forecast period (2018–2026).
Regenerative Medicine Market PPT 2021: Size, Growth, Demand and Forecast till...IMARC Group
As per the latest report by IMARC Group,the global Regenerative medicine market size reached a strong growth in 2020.
Regenerative medicines refer to an interdisciplinary field that plays a vital role in tissue and organ transplants.
Biodefense Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by T...IMARC Group
According to the latest report by IMARC Group,the global biodefense market size reached US$ 12.7 Billion by 2020.
Biodefense includes the utilization of several medical and military measures that are taken to safeguard individuals against bioterrorism.
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...IMARC Group
The global Pompe disease treatment market size reached US$ 1.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.3 Billion by 2032, exhibiting a growth rate (CAGR) of 2.58% during 2024-2032.
More Info:- https://www.imarcgroup.com/pompe-disease-treatment-market
Corporate Wellness Market by Product Type, Distribution Channel, End User 202...IMARC Group
The global corporate wellness market size reached US$ 66.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 118.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/corporate-wellness-market
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032IMARC Group
The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/migraine-drugs-market
Empty Capsules Market by Product Type, Distribution Channel, End User 2023-2028IMARC Group
The global empty capsules market size reached US$ 2.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 7.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/empty-capsules-market
MarketResearchReports.com has announced the addition of “Forecast of Global Clinical Trial Supplies Consumption Market Report 2023” research report to their offering. See more at- http://mrr.cm/wWQ
This document summarizes a report on the global zoonotic disease treatment market. Zoonotic diseases are those spread between animals and humans. The market is driven by factors like population growth, urbanization, and increased consumption of animal proteins. However, lack of disease awareness, high research costs, and drug prices restrain the market. The market is expected to grow due to rising meat consumption and income levels in developing nations. North America currently dominates the market but Asia Pacific is expected to experience increased zoonotic disease prevalence due to poor sanitation. The report provides an overview, key drivers and restraints, regional analysis, and profiles major market players.
Addiction Treatment Market by Product Type, Distribution Channel, End User 20...IMARC Group
The global addiction treatment market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.76% during 2024-2032.
More Info:- https://www.imarcgroup.com/addiction-treatment-market
Pharmaceutical industry pestel analysisRahul Pagaria
The pharmaceutical industry in India is a rapidly growing sector that produces low-cost, high-quality drugs. It has a total market size of over $20 billion and has grown at around 12.5% annually over the past five years. Key players in the industry include Ranbaxy, Dr. Reddy's, Cipla, and Lupin. A PESTEL analysis identified political issues like price controls, social factors like an aging population and increased patient expectations, economic challenges from the global crisis, opportunities from new technologies, and an increasing focus on the environmental impact of the industry.
This document summarizes a report on the biostimulants market. It grew steadily from 2020 to 2027 with a compound annual growth rate expected to improve. Biostimulants are used in agriculture to enhance plant growth and are segmented by application into foliar, soil, and seed treatments. They are also segmented by crop type into row crops, fruits and vegetables, turfs and ornamentals, and other crop types. The document provides an overview of key players in the biostimulants market and requests a free PDF sample of the full report.
Human Insulin Market Growth, Demand and Challenges of the Key Industry Player...IMARC Group
The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
More Info:- https://www.imarcgroup.com/human-insulin-market
Sports Medicine Market Report in PPT: Top Companies, Trends and Future Detail...IMARC Group
Looking forward, the sports medicine market value is projected to reach a strong growth during the forecast period (2022-2027).
More info:- https://www.imarcgroup.com/sports-medicine-market
Cell Therapy Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global cell therapy market size reached US$ 11.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 32.1 Billion by 2028, exhibiting a growth rate (CAGR) of 17.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/cell-therapy-market
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
1. Global Precision
Medicine Market
Focus on Precision Medicine
Ecosystem, Applications,
13 Countries Mapping, and
Competitive Landscape -
Analysis and Forecast:
2018-2028
January 2019
3. Global Precision Medicine Market
All rights reserved at BIS Research 3
Click Here to Nominate Yourself or
Someone You Know Now
4. Global Precision Medicine Market
All rights reserved at BIS Research 4
Preface
In recent times, the increased prevalence of several chronic diseases, including cancer, diabetes, and
cardiovascular diseases, is considered to be one of the leading causes of mortality. With the increasing
life span and life expectancy, the geriatric population is growing at a fast pace and is expected to witness
a surge in the future. Consequently, the surge in demand for better treatment outcomes is leading to
the ascending need for early diagnosis and tailored medication. The growth of the personalized
medicine market over the last few years (2010-2017) has been colossal. Novel technologies, including
next-generation sequencing and biomarker assays, are being rapidly approved by regulatory bodies
including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), thus
expanding the arsenal of tools accessible to support the development and adoption of novel vaccines
over “one-size-fits-all” therapies and treatment.
In order to facilitate the development of targeted vaccines, the number of commercialized biologics and
delivery techniques has increased, especially in the case of infectious diseases and cancer. The newly
developed techniques and drugs for target diseases not only facilitate parallel development of targeted
drugs but also provide essential information for patient classification for enabling effective genome study
and optimizing corresponding treatment. Moreover, targeted therapies help healthcare professionals to
treat patients with great efficacy and less time duration. Thus, novel vaccines eliminate the uncertainty
of trial-and-error method of medications and reduce unnecessary healthcare expenditure.
The following report “Global Precision Medicine Market” explains the importance of the personalized
medicines, the individualized therapies, the technological advancements involved with the development
of different technologies in the precision medicine ecosystem, the factor affecting growth of the market,
and the challenges faced by the key players in the market. The report also covers the competitive
landscape of the market, industry attractiveness, growth potential, and market dynamics. The
intensifying cancer incidences, rising geriatric population, increasing health consciousness, and
expanding adoption of vaccine approach over “one-drug-for-all-patients” treatment method in
developed as well as developing economies are expected to be the major factors for the growth of the
market.
The report has been segmented into three sections namely, ecosystem, application, and region. Each
segment is further sub-segmented and provides data for the market revenue from 2017 to 2028.
5. Global Precision Medicine Market
All rights reserved at BIS Research 5
Key questions answered in the report:
What are the major market drivers, challenges, and opportunities in the global precision
medicine market?
What are the underlying structures resulting in the emerging trends within the precision
medicine market?
What was the market value of the leading segments and sub-segments of the global precision
medicine market in 2017?
How will each segment of the global precision medicine market grow during the forecast
period and what will be the revenue generated by each of the segments by the end of 2028?
What are the influencing factors that may affect the market share of the key players?
How will the industry evolve during the forecast period 2018- 2028?
What are the key developmental strategies which are implemented by the key players to
sustain in the competitive market?
What are the key ecosystem type in the global precision medicine market? What are the
major benefits of each type?
How has the market been segmented on the basis of application type? Which application
type is dominating the global precision medicine market and what is the reason behind such
domination?
Which ecosystem type is having the most promising growth and in which application type?
What is the market share of each of the companies in the global precision medicine market
and what are their contributions?
What is the scope of each type of ecosystem in North America, Europe, Asia-Pacific, Latin
America, and Rest-of-the-World?
What is the growth potential of precision medicine in each region, including North America,
Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
BIS Healthcare
January 2019
6. Global Precision Medicine Market
All rights reserved at BIS Research 6
Table of Contents
Executive Summary ........................................................................................................ 40
1. Market Overview................................................................................................... 75
1.1 Introduction ..................................................................................................... 75
1.2 Precision Medicine: A Frontier in the Genesis of Patient-centric
Medicine........................................................................................................... 77
1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to
Individually Tailored Therapy......................................................................... 78
1.4 Initiatives and Programs................................................................................. 82
1.5 Assumptions and Limitations for Market Size Calculations ....................... 86
1.6 Precision Medicine: Enabling Technologies ................................................ 86
1.6.1 Innovators ............................................................................................. 87
1.6.1.1 3D DNA Printing ..................................................................................... 87
1.6.1.1.1 Introduction ....................................................................................... 87
1.6.1.1.2 Role of 3D DNA Printing ................................................................... 87
1.6.1.2 RNA-Seq ................................................................................................ 88
1.6.1.2.1 Introduction ....................................................................................... 88
1.6.1.2.2 Role of RNA-Seq in Precision Medicine............................................ 88
1.6.1.2.3 Key Players....................................................................................... 88
1.6.1.3 4D Molecular Imaging............................................................................. 89
1.6.1.3.1 Introduction ....................................................................................... 89
1.6.1.3.2 Role of 4D Molecular Imaging in Precision Medicine ........................ 89
1.6.1.3.3 Key Players....................................................................................... 89
1.6.2 Early Adopters...................................................................................... 89
1.6.2.1 CRISPR.................................................................................................. 89
1.6.2.1.1 Introduction ....................................................................................... 89
1.6.2.1.2 Role of CRISPR in Precision Medicine ............................................. 90
1.6.2.1.3 Key Players....................................................................................... 91
1.6.2.2 Blockchain.............................................................................................. 91
1.6.2.2.1 Introduction ....................................................................................... 91
1.6.2.2.2 Role of Blockchain in Precision Medicine.......................................... 91
1.6.2.2.3 Key Players....................................................................................... 92
7. Global Precision Medicine Market
All rights reserved at BIS Research 7
1.6.2.3 Imaging Informatics ................................................................................ 92
1.6.2.3.1 Introduction ....................................................................................... 92
1.6.2.3.2 Role of Imaging Informatics in Precision Medicine............................ 92
1.6.2.3.3 Key Players....................................................................................... 93
1.6.3 Early Majority........................................................................................ 93
1.6.3.1 Artificial Intelligence (AI)......................................................................... 93
1.6.3.1.1 Introduction ....................................................................................... 93
1.6.3.1.2 Role of Artificial Intelligence in Precision Medicine ........................... 93
1.6.3.1.3 Key Players....................................................................................... 93
1.6.3.2 Circulating free DNA (cfDNA)................................................................. 94
1.6.3.2.1 Introduction ....................................................................................... 94
1.6.3.2.2 Role of cfDNA in Precision Medicine................................................. 94
1.6.3.2.3 Key Players....................................................................................... 94
1.6.3.3 Big Data.................................................................................................. 95
1.6.3.3.1 Introduction ....................................................................................... 95
1.6.3.3.2 Role of Big Data in Precision Medicine ............................................. 95
1.6.3.3.3 Key Players....................................................................................... 96
1.6.3.4 Next-Generation Sequencing (NGS) ...................................................... 96
1.6.3.4.1 Introduction ....................................................................................... 96
1.6.3.4.2 Role of NGS in Precision Medicine ................................................... 97
1.6.3.4.3 Key Players....................................................................................... 97
1.6.3.5 Health Informatics................................................................................... 97
1.6.3.5.1 Introduction ....................................................................................... 97
1.6.3.5.2 Role of Health informatics in Precision Medicine .............................. 98
1.6.3.5.3 Key players ....................................................................................... 99
1.6.3.6 Bioinformatics......................................................................................... 99
1.6.3.6.1 Introduction ....................................................................................... 99
1.6.3.6.2 Role of Bioinformatics in Precision Medicine .................................... 99
1.6.3.6.3 Key Players....................................................................................... 99
1.6.4 Late Majority ....................................................................................... 100
1.6.4.1 Polymerase Chain Reactions (PCR) .................................................... 100
1.6.4.1.1 Introduction ..................................................................................... 100
1.6.4.1.2 Role of PCR in Precision Medicine ................................................. 100
8. Global Precision Medicine Market
All rights reserved at BIS Research 8
1.6.4.1.3 Key players ..................................................................................... 100
1.6.4.2 Microarray ............................................................................................ 100
1.6.4.2.1 Role of Microarray in Precision Medicine........................................ 101
1.6.4.2.2 Key Players..................................................................................... 101
2. Market Dynamics................................................................................................ 102
2.1 Impact Analysis............................................................................................. 103
2.2 Market Drivers ............................................................................................... 104
2.2.1 Advancement of Sequencing Technologies .................................... 104
2.2.2 Rising Prevalence of Chronic Diseases ........................................... 107
2.2.3 Growing Demand for Preventive Care.............................................. 110
2.2.4 Shifting the Significance in Medicine, from Reaction to
Prevention........................................................................................... 111
2.2.5 Reducing Adverse Drug Reactions Through
Pharmacogenomics Test................................................................... 111
2.2.6 Potential to Reduce the Overall Healthcare Cost Across the
Globe ................................................................................................... 112
2.3 Market Restraints.......................................................................................... 112
2.3.1 Unified Framework for Data Integration ........................................... 112
2.3.2 Limited Knowledge About Precision Medicine Application ........... 113
2.3.3 Lack of Robust Reimbursement Landscape.................................... 114
2.3.4 Regulatory Hurdles ............................................................................ 114
2.4 Market Opportunities .................................................................................... 117
2.4.1 Targeted Gene Therapy ..................................................................... 117
2.4.2 Expansion into the Emerging Markets ............................................. 118
2.4.3 Collaboration and Partnerships Across Value Chain Would
Accelerate the Market Entry .............................................................. 119
3. Competitive Insights .......................................................................................... 121
3.1 Key Developments and Strategies .............................................................. 122
3.1.1 Joint Ventures, Partnerships, Agreements, and Collaborations.... 123
3.1.2 Product launches, Enhancements, and Upgradation...................... 124
3.1.3 Product Approvals ............................................................................. 126
3.1.4 Merger and Acquisitions.................................................................... 127
3.1.5 Business Expansion .......................................................................... 128
9. Global Precision Medicine Market
All rights reserved at BIS Research 9
3.1.6 Other Developments .......................................................................... 129
3.2 Market Share Analysis.................................................................................. 130
3.2.1 Market Share Analysis by Applied Sciences, 2017.......................... 131
3.2.2 Market Share Analysis by Precision Diagnostics, 2017.................. 133
3.2.3 Market Share Analysis by Precision Therapeutics, 2017................ 135
3.2.4 Market Share Analysis by Digital Health and IT, 2017..................... 136
3.3 Industry Attractiveness ................................................................................ 137
3.3.1 Definition of Suppliers and Buyers in the Precision Medicine
Market.................................................................................................. 138
3.3.2 Bargaining Power of Suppliers ......................................................... 139
3.3.3 Bargaining Power of Buyers ............................................................. 140
3.3.4 Threat of New Entrants ...................................................................... 141
3.3.5 Threat of Substitute Products ........................................................... 142
3.3.6 Intensity of Competitive Rivalry........................................................ 144
3.4 Supply Chain Analysis.................................................................................. 145
4. Industry Insights................................................................................................. 147
4.1 Patent Analysis ............................................................................................. 147
4.2 Legal Requirements and Regulations ......................................................... 148
4.3 Pipeline Analysis........................................................................................... 150
5. Global Precision Medicine Market (by Ecosystem) ......................................... 157
5.1 Overview ........................................................................................................ 157
5.2 Applied Sciences .......................................................................................... 160
5.2.1 Genomics............................................................................................ 162
5.2.1.1 Polymerase Chain Reaction (PCR) ...................................................... 165
5.2.1.2 Precision Medicine Next-Generation Sequencing (PM NGS)............... 168
5.2.1.3 Genome Editing.................................................................................... 174
5.2.1.4 Other Technologies .............................................................................. 178
5.2.2 Pharmacogenomics ........................................................................... 179
5.2.3 Other Applied Sciences ..................................................................... 188
5.3 Precision Diagnostics................................................................................... 189
5.3.1 Molecular Diagnostics (MDx) ............................................................ 192
5.3.1.1 Non-invasive Prenatal Testing (NIPT) .................................................. 196
10. Global Precision Medicine Market
All rights reserved at BIS Research 10
5.3.1.2 Companion Diagnostics........................................................................ 200
5.3.1.3 Liquid Biopsy........................................................................................ 209
5.3.1.4 Other Molecular Diagnostics ................................................................ 213
5.3.2 Medical Imaging.................................................................................. 216
5.3.2.1 Imaging Analytics ................................................................................. 220
5.3.2.2 Imaging Computer-Aided Detection (CADx)......................................... 221
5.4 Digital Health and Information Technology ................................................ 222
5.4.1 Clinical Decision Support Systems (CDSS) ..................................... 227
5.4.2 Big Data Analytics.............................................................................. 228
5.4.3 IT Infrastructure.................................................................................. 232
5.4.4 Genomics Informatics........................................................................ 234
5.4.5 In-Silico Informatics ........................................................................... 237
5.4.6 Mobile Health ...................................................................................... 238
5.5 Precision Therapeutics................................................................................. 241
5.5.1 Clinical Trials ...................................................................................... 242
5.5.2 Cell Therapy........................................................................................ 244
5.5.3 Drug Discovery and Research .......................................................... 247
5.5.4 Gene Therapy ..................................................................................... 250
6. Global Precision Medicine Market (by Application) ........................................ 254
6.1 Overview ........................................................................................................ 254
6.2 Oncology........................................................................................................ 257
6.2.1 Government Initiatives....................................................................... 259
6.2.2 Key Insights ........................................................................................ 260
6.2.3 Drivers and Challenges...................................................................... 261
6.2.4 Cancer Precision Medicine Drugs and Indications ......................... 261
6.2.5 Recent Key Developments ................................................................ 263
6.3 Infectious Diseases....................................................................................... 264
6.3.1 Infectious Diseases Precision Medicine Drugs and Indications .... 267
6.4 Neurology/Physiatry ..................................................................................... 267
6.4.1 Neurology Precision Medicine Drugs and Indications.................... 269
6.5 Cardiovascular .............................................................................................. 270
6.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and
Indications .......................................................................................... 272
11. Global Precision Medicine Market
All rights reserved at BIS Research 11
6.6 Lifestyle and Endocrinology ........................................................................ 272
6.6.1 Endocrinology Precision Medicine Drugs and Indications ............ 274
6.7 Gastroenterology .......................................................................................... 274
6.7.1 Gastroenterology Precision Medicine Drugs and Indications........ 275
6.8 Other Applications ........................................................................................ 276
6.8.1 Precision Drugs for Other Applications ........................................... 277
7. Global Precision Medicine Market (by Region)................................................ 280
7.1 Overview ........................................................................................................ 280
7.2 North America ............................................................................................... 282
7.2.1 North America Precision Medicine Market Dynamics..................... 283
7.2.2 The U.S................................................................................................ 286
7.2.2.1 Market Statistics ................................................................................... 286
7.2.2.2 Overview of Precision Medicine ........................................................... 287
7.2.2.3 Key Trends........................................................................................... 287
7.2.2.4 Promoting Factors ................................................................................ 288
7.2.2.5 Recent Key Developments................................................................... 288
7.2.2.6 Funding Scenario/Investments ............................................................. 289
7.2.2.7 Regulatory Scenario............................................................................. 289
7.2.2.8 Key Players .......................................................................................... 290
7.2.3 Canada ................................................................................................ 290
7.2.3.1 Market Statistics ................................................................................... 290
7.2.3.2 Overview of Precision Medicine ........................................................... 291
7.2.3.3 Key Trends........................................................................................... 292
7.2.3.4 Promoting Factors ................................................................................ 292
7.2.3.5 Recent Key Developments................................................................... 292
7.2.3.6 Funding Scenario ................................................................................. 293
7.2.3.7 Regulatory Scenario............................................................................. 293
7.2.3.8 Key Players .......................................................................................... 293
7.3 Europe............................................................................................................ 294
7.3.1 Europe Precision Medicine Market Dynamics ................................. 295
7.3.2 Germany.............................................................................................. 298
7.3.2.1 Market Statistics ................................................................................... 298
7.3.2.2 Overview of Precision Medicine ........................................................... 299
14. Global Precision Medicine Market
All rights reserved at BIS Research 14
7.4.4.5 Recent Key Developments................................................................... 332
7.4.4.6 Key Players .......................................................................................... 333
7.4.5 Rest-of-Asia-Pacific (RoAPAC) ......................................................... 333
7.4.5.1 Market Statistics ................................................................................... 333
7.4.5.2 Singapore............................................................................................. 335
7.4.5.2.1 Regulatory Framework.................................................................... 335
7.4.5.3 South Korea ......................................................................................... 335
7.4.5.4 Vietnam ................................................................................................ 336
7.5 Latin America ................................................................................................ 337
7.5.1 Latin America Precision Medicine Market Dynamics...................... 339
7.5.2 Brazil.................................................................................................... 341
7.5.2.1 Market Statistics ................................................................................... 341
7.5.2.2 Overview of Precision Medicine ........................................................... 342
7.5.3 Mexico ................................................................................................. 343
7.5.3.1 Market Statistics ................................................................................... 343
7.5.3.2 Overview of Precision Medicine ........................................................... 344
7.5.3.3 Recent Key Developments................................................................... 345
7.5.4 Rest-of-Latin America (RoLA) ........................................................... 345
7.5.4.1 Market Statistics ................................................................................... 345
7.6 Rest-of-the-World (RoW) .............................................................................. 346
7.6.1 Market Statistics................................................................................. 346
7.6.1.1 Middle East Precision Market Dynamics .............................................. 348
7.6.1.2 Africa Precision Medicine Market Dynamics......................................... 349
7.6.1.3 Israel..................................................................................................... 350
7.6.1.4 Saudi Arabia......................................................................................... 351
7.6.1.5 United Arab Emirates ........................................................................... 351
7.6.1.6 South Africa.......................................................................................... 352
7.6.1.7 Russia .................................................................................................. 353
8. Company Profile ................................................................................................. 354
8.1 Abbott Laboratories...................................................................................... 354
8.1.1 Company Overview ............................................................................ 354
8.1.2 Role of Abbott Laboratories, Inc.in the Global Precision
Medicine Market.................................................................................. 354
15. Global Precision Medicine Market
All rights reserved at BIS Research 15
8.1.3 Key Insights about Financial Health of the Company..................... 358
8.1.4 SWOT Analysis................................................................................... 359
8.2 Almac Group Ltd. .......................................................................................... 360
8.2.1 Company Overview ............................................................................ 360
8.2.2 Role of Almac Group Ltd. in the Global Precision Medicine
Market.................................................................................................. 360
8.2.3 SWOT Analysis................................................................................... 361
8.3 Amgen Inc...................................................................................................... 362
8.3.1 Company Overview ............................................................................ 362
8.3.2 Role of Amgen Inc. in the Global Precision Medicine Market ........ 362
8.3.3 Key Insights about Financial Health of the Company..................... 364
8.3.4 SWOT Analysis................................................................................... 365
8.4 ANGLE plc ..................................................................................................... 366
8.4.1 Company Overview ............................................................................ 366
8.4.2 Role of ANGLE plc in the Global Precision Medicine Market ......... 366
8.4.3 Key Insights about Financial Health of the Company..................... 368
8.4.4 SWOT Analysis................................................................................... 369
8.5 Astellas Pharma Inc. ..................................................................................... 370
8.5.1 Company Overview ............................................................................ 370
8.5.2 Role of Astellas Pharma Inc.in the Global Precision Medicine
Market.................................................................................................. 370
8.5.3 Key Insights about Financial Health of the Company..................... 372
8.5.4 SWOT Analysis................................................................................... 373
8.6 Astra Zeneca PLC ......................................................................................... 374
8.6.1 Company Overview ............................................................................ 374
8.6.2 Role of Astra Zeneca PLC in the Global Precision Medicine
Market.................................................................................................. 374
8.6.3 Key Insights about Financial Health of the Company..................... 377
8.6.4 SWOT Analysis................................................................................... 378
8.7 ASURAGEN INC. ........................................................................................... 379
8.7.1 Company Overview ............................................................................ 379
8.7.2 Role of ASURAGEN Inc. in the Global Precision Medicine
Market.................................................................................................. 379
8.7.3 SWOT Analysis................................................................................... 380
16. Global Precision Medicine Market
All rights reserved at BIS Research 16
8.8 Bio-Rad Laboratories, Inc............................................................................. 381
8.8.1 Company Overview ............................................................................ 381
8.8.2 Role of Bio-Rad Laboratories, Inc.in the Global Precision
Medicine Market.................................................................................. 381
8.8.3 Key Insights about Financial Health of the Company..................... 384
8.8.4 SWOT Analysis................................................................................... 385
8.9 bioMérieux SA. .............................................................................................. 386
8.9.1 Company Overview ............................................................................ 386
8.9.2 Role of bioMérieux SA. in the Global Precision Medicine
Market.................................................................................................. 386
8.9.3 Key Insights about Financial Health of the Company..................... 389
8.9.4 SWOT Analysis................................................................................... 390
8.10 Bristol-Myers Squibb Company................................................................... 391
8.10.1 Company Overview ............................................................................ 391
8.10.2 Role of Bristol-Myers Squibb Company in the Global
Precision Medicine Market ................................................................ 391
8.10.3 Key Insights about Financial Health of the Company..................... 393
8.10.4 SWOT Analysis................................................................................... 394
8.11 Canon Inc....................................................................................................... 395
8.11.1 Company Overview ............................................................................ 395
8.11.2 Role of Canon Inc. in the Global Precision Medicine Market ......... 395
8.11.3 Key Insights about Financial Health of the Company..................... 396
8.11.4 SWOT Analysis................................................................................... 399
8.12 CETICS Healthcare Technologies GmbH.................................................... 400
8.12.1 Company Overview ............................................................................ 400
8.12.2 Role CETICS Healthcare Technologies GmbHin the Global
Precision Medicine Market ................................................................ 400
8.12.3 Figure SWOT Analysis....................................................................... 401
8.13 Danaher Corporation .................................................................................... 402
8.13.1 Company Overview ............................................................................ 402
8.13.2 Role of Danaher Corporation in the Global Precision Medicine
Market.................................................................................................. 402
8.13.3 Key Insights about Financial Health of the Company..................... 405
8.13.4 SWOT Analysis................................................................................... 406
17. Global Precision Medicine Market
All rights reserved at BIS Research 17
8.14 Eli Lilly and Company Limited ..................................................................... 407
8.14.1 Company Overview ............................................................................ 407
8.14.2 Role of Eli Lilly and Company Limited in the Global Precision
Medicine Market.................................................................................. 407
8.14.3 Key Insights about Financial Health of the Company..................... 410
8.14.4 SWOT Analysis................................................................................... 411
8.15 Epic Sciences, Inc......................................................................................... 412
8.15.1 Company Overview ............................................................................ 412
8.15.2 Role Epic Sciences, Inc. in the Global Precision Medicine
Market.................................................................................................. 412
8.15.3 SWOT Analysis................................................................................... 413
8.16 F. Hoffmann-La Roche AG............................................................................ 414
8.16.1 Company Overview ............................................................................ 414
8.16.2 Role of F.Hoffman-LA Roche AG in the Global Precision
Medicine Market.................................................................................. 414
8.16.3 Key Insights about Financial Health of the Company..................... 417
8.16.4 SWOT Analysis................................................................................... 418
8.17 GE Corporation ............................................................................................. 419
8.17.1 Company Overview ............................................................................ 419
8.17.2 Role of GE Corporation in the Global Precision Medicine
Market.................................................................................................. 419
8.17.3 Key Insights about Financial Health of the Company..................... 422
8.17.4 SWOT Analysis................................................................................... 423
8.18 Gilead Sciences, Inc. .................................................................................... 424
8.18.1 Company Overview ............................................................................ 424
8.18.2 Role of Gilead Sciences, Inc. in the Global Precision Medicine
Market.................................................................................................. 424
8.18.3 Key Insights about Financial Health of the Company..................... 427
8.18.4 SWOT Analysis................................................................................... 428
8.19 GlaxoSmithKline Plc ..................................................................................... 429
8.19.1 Company Overview ............................................................................ 429
8.19.2 Role of GlaxoSmithKline Plc in the Global Precision Medicine
Market.................................................................................................. 429
8.19.3 Key Insights about Financial Health of the Company..................... 432
8.19.4 SWOT Analysis................................................................................... 433
18. Global Precision Medicine Market
All rights reserved at BIS Research 18
8.20 IBM Corporation ............................................................................................ 434
8.20.1 Company Overview ............................................................................ 434
8.20.2 Role of IBM Corporation in the Global Precision Medicine
Market.................................................................................................. 434
8.20.3 Key Insights about Financial Health of the Company..................... 437
8.20.4 SWOT Analysis................................................................................... 438
8.21 Illumina, Inc. .................................................................................................. 439
8.21.1 Company Overview ............................................................................ 439
8.21.2 Role of Illumina, Inc. in the Global Precision Medicine Market ...... 439
8.21.3 Key Insights about Financial Health of the Company..................... 442
8.21.4 SWOT Analysis................................................................................... 443
8.22 Intomics A/S .................................................................................................. 444
8.22.1 Company Overview ............................................................................ 444
8.22.2 Role Intomics A/S in the Global Precision Medicine Market .......... 444
8.22.3 SWOT Analysis................................................................................... 445
8.23 Johnson & Johnson...................................................................................... 446
8.23.1 Company Overview ............................................................................ 446
8.23.2 Role of Johnson and Johnson in the Global Precision
Medicine Market.................................................................................. 446
8.23.3 Key Insights about Financial Health of the Company..................... 449
8.23.4 SWOT Analysis................................................................................... 450
8.24 Konica Minolta, Inc. ...................................................................................... 451
8.24.1 Company Overview ............................................................................ 451
8.24.2 Role of Konica Minolta, Inc. in the Global Precision Medicine
Market.................................................................................................. 451
8.24.3 Key Insights about Financial Health of the Company..................... 452
8.24.4 SWOT Analysis................................................................................... 455
8.25 Laboratory Corporation of America ............................................................ 456
8.25.1 Company Overview ............................................................................ 456
8.25.2 Role of Lab Corporation of America in the Global Precision
Medicine Market.................................................................................. 456
8.25.3 Key Insights about Financial Health of the Company..................... 457
8.25.4 SWOT Analysis................................................................................... 459
8.26 MDx Health, Inc. ............................................................................................ 460
19. Global Precision Medicine Market
All rights reserved at BIS Research 19
8.26.1 Company Overview ............................................................................ 460
8.26.2 Role of MDx Health, Inc. in the Global Precision Medicine
Market.................................................................................................. 460
8.26.3 Key Insights about Financial Health of the Company..................... 462
8.26.4 SWOT Analysis................................................................................... 463
8.27 Menarini Silicon Biosystems, Inc. ............................................................... 464
8.27.1 Company Overview ............................................................................ 464
8.27.2 Role Menarini Silicon Biosystems, Inc. in the Global Precision
Medicine Market.................................................................................. 464
8.27.3 SWOT Analysis................................................................................... 466
8.28 Merck & Co., Inc. ........................................................................................... 467
8.28.1 Company Overview ............................................................................ 467
8.28.2 Role of Merck & Co., Inc. in the Global Precision Medicine
Market.................................................................................................. 467
8.28.3 Key Insights about Financial Health of the Company..................... 470
8.28.4 SWOT Analysis................................................................................... 471
8.29 Myriad Genetics, Inc. .................................................................................... 472
8.29.1 Company Overview ............................................................................ 472
8.29.2 Role of Myriad Genetics, Inc. in the Global Precision Medicine
Market.................................................................................................. 472
8.29.3 Key Insights about Financial Health of the Company..................... 475
8.29.4 SWOT Analysis................................................................................... 476
8.30 Novartis AG. .................................................................................................. 477
8.30.1 Company Overview ............................................................................ 477
8.30.2 Role of Novartis AG in the Global Precision Medicine Market ....... 477
8.30.3 Key Insights about Financial Health of the Company..................... 480
8.30.4 SWOT Analysis................................................................................... 481
8.31 Oracle Corporation. ...................................................................................... 482
8.31.1 Company Overview ............................................................................ 482
8.31.2 Role of Oracle Corporation in the Global Precision Medicine
Market.................................................................................................. 482
8.31.3 Key Insights about Financial Health of the Company..................... 484
8.31.4 SWOT Analysis................................................................................... 485
8.32 Pacific Biosciences of California, Inc.......................................................... 486
20. Global Precision Medicine Market
All rights reserved at BIS Research 20
8.32.1 Company Overview ............................................................................ 486
8.32.2 Role of Pacific Biosciences of California, Inc. in the Global
Precision Medicine Market ............................................................... 486
8.32.3 Key Insights about Financial Health of the Company..................... 488
8.32.4 SWOT Analysis................................................................................... 489
8.33 Partek, Inc...................................................................................................... 490
8.33.1 Company Overview ............................................................................ 490
8.33.2 Role Partek, Inc. in the Global Precision Medicine Market ............. 490
8.33.3 SWOT Analysis................................................................................... 491
8.34 Pfizer, Inc. ...................................................................................................... 492
8.34.1 Company Overview ............................................................................ 492
8.34.2 Role of Pfizer, Inc. in the Global Precision Medicine Market.......... 492
8.34.3 Key Insights about Financial Health of the Company..................... 495
8.34.4 SWOT Analysis................................................................................... 496
8.35 QIAGEN N.V................................................................................................... 497
8.35.1 Company Overview ............................................................................ 497
8.35.2 Role of Qiagen N.V in the Global Precision Medicine Market......... 497
8.35.3 Key Insights about Financial Health of the Company..................... 501
8.35.4 SWOT Analysis................................................................................... 502
8.36 Quest Diagnostics Inc................................................................................... 503
8.36.1 Company Overview ............................................................................ 503
8.36.2 Role of Quest Diagnostics Inc. in the Global Precision
Medicine Market.................................................................................. 503
8.36.3 Key Insights about Financial Health of the Company..................... 504
8.36.4 SWOT Analysis................................................................................... 506
8.37 Randox Laboratories Ltd.............................................................................. 507
8.37.1 Company Overview ............................................................................ 507
8.37.2 Role of Randox Laboratories Ltd. in the Global Precision
Medicine Market.................................................................................. 507
8.37.3 SWOT Analysis................................................................................... 508
8.38 Sanofi SA ....................................................................................................... 509
8.38.1 Company Overview ............................................................................ 509
8.38.2 Role of Sanofi SA in the Global Precision Medicine Market........... 509
8.38.3 Key Insights about Financial Health of the Company..................... 512
21. Global Precision Medicine Market
All rights reserved at BIS Research 21
8.38.4 SWOT Analysis................................................................................... 513
8.39 Sysmex Corporation ..................................................................................... 514
8.39.1 Company Overview ............................................................................ 514
8.39.2 Role of Sysmex Corporation in the Global Precision Medicine
Market.................................................................................................. 514
8.39.3 Key Insights about Financial Health of the Company..................... 516
8.39.4 SWOT Analysis................................................................................... 517
8.40 Teva Pharmaceuticals Industries Ltd.......................................................... 518
8.40.1 Company Overview ............................................................................ 518
8.40.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global
Precision Medicine Market ............................................................... 518
8.40.3 Key Insights about Financial Health of the Company..................... 521
8.40.4 SWOT Analysis................................................................................... 522
8.41 Thermo Fisher Scientific, Inc. ...................................................................... 523
8.41.1 Company Overview ............................................................................ 523
8.41.2 Role of Thermo Fisher Scientific Inc. in the Global Precision
Medicine Market.................................................................................. 523
8.41.3 Key Insights about Financial Health of the Company..................... 526
8.41.4 SWOT Analysis................................................................................... 527
8.42 TrovaGene, Inc. ............................................................................................. 528
8.42.1 Company Overview ............................................................................ 528
8.42.2 Role of TrovaGene, Inc. in the Global Precision Medicine
Market.................................................................................................. 528
8.42.3 SWOT Analysis................................................................................... 530
9. Report Scope and Methodology........................................................................ 531
9.1 Scope of the Report ...................................................................................... 531
9.2 Research Methodology................................................................................. 532
9.2.1 Primary Research............................................................................... 534
9.2.2 Secondary Research.......................................................................... 535
9.2.3 Key Data Points from Primary Resources........................................ 536
9.2.4 Key Data Points from Secondary Sources....................................... 536
9.2.5 Data Triangulation.............................................................................. 537
10. List of Annexures ............................................................................................... 541
22. Global Precision Medicine Market
All rights reserved at BIS Research 22
10.1 Recent Key Developments and Strategies.................................................. 541
10.2 Product Mapping........................................................................................... 541
10.3 Patent Analysis ............................................................................................. 541
10.4 Funding Scenario.......................................................................................... 541
10.5 List of Precision Medicine Drugs................................................................. 541
10.6 Patent Landscape and Regulatory Bodies.................................................. 541
10.7 Cancer Incidence Datasheet ........................................................................ 541
10.8 List of Approved Products ........................................................................... 541
10.9 Competitive Mapping.................................................................................... 541
10.10 PM Initiatives ................................................................................................. 541
10.11 List of Universities ........................................................................................ 541
10.12 List of Prominent Center of Excellence (CoE)............................................ 541
10.13 Data on Partnerships by Academics, CoE and Industry............................ 541
10.14 Precision Medicine Drugs Pipeline Analysis.............................................. 541
23. Global Precision Medicine Market
All rights reserved at BIS Research 23
List of Tables
Table 1: Comparison of China and the U.S. Healthcare Statistics......................................................50
Table 1.1: Initiatives and Programs.....................................................................................................82
Table 2.1: Impact Analysis................................................................................................................103
Table 2.2: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030) .........107
Table 2.3: Cancer Incidence by WHO Region, 2012 (Thousands) ...................................................109
Table 2.4: Cancer Incidence Type in Thousand, 2012 (WHO) .........................................................109
Table 2.5: Policy and Guidance Documents from the U.S. FDA.......................................................116
Table 4.1: Pipeline Analysis..............................................................................................................150
Table 4.2: Precision Medicine Drugs Pipeline Analysis.....................................................................153
Table 5.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling................182
Table 5.2: Key Approved Therapeutics with FDA Mandated Companion Diagnostics Tests ...........202
Table 5.3: List of FDA Approved Companion Diagnostics ................................................................203
Table 5.4: Commercially Available Primary and Secondary Analysis Tools Providers......................237
Table 6.1: Cancer Precision Medicine Drugs and Indications...........................................................261
Table 6.2: Recent Key Developments ..............................................................................................263
Table 6.3: Infectious Diseases Precision Medicine Drugs and Indications........................................267
Table 6.4: Neurology Precision Medicine Drugs and Indications ......................................................269
Table 6.5: Cardiovascular Precision Medicine Drugs/Tests/ and Indications....................................272
Table 6.6: Endocrinology Precision Medicine Drugs and Indications................................................274
Table 6.7: Gastroenterology Precision Medicine Drugs and Indications ...........................................275
Table 6.8: Precision Drugs for Other Applications ............................................................................277
Table 7.1: Funding scenario in Universities ......................................................................................308
24. Global Precision Medicine Market
All rights reserved at BIS Research 24
List of Figures
Figure 1: Precision Medicine: Treatment Tailored to an Individual’s Genetic Structure.......................40
Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care .........................................41
Figure 3: Chronic Conditions: Key Statistics: 2017 .............................................................................42
Figure 4: Long-Term Growth Drivers ..................................................................................................43
Figure 5: Impact Analysis....................................................................................................................44
Figure 6: Global Precision Medicine Market Snapshot .......................................................................45
Figure 7: Dominating Segments of Global Precision Medicine Market, 2017 and 2028......................46
Figure 8: Global Precision Medicine Market (by Ecosystem), 2017 and 2028 ....................................46
Figure 9: Global Precision Medicine Market, (by Application), 2017 and 2028 ...................................47
Figure 10: Global Precision Medicine Market (by Region), 2017 and 2028 ........................................49
Figure 11: Notable Areas of Strategic Focus across Influential Countries...........................................52
Figure 12: Strategies Incorporated to Expand the Global Reach........................................................54
Figure 13: Precision Medicine Funding for Academic Institutions and Research Organizations.........55
Figure 14: A Persuasive Market Entry Strategy for Diagnostics and Pharma & Biotech Companies to
Capitalize on Precision Medicine........................................................................................................60
Figure 15: Plausible Market Penetration Strategy to Shape the Future of Healthcare ........................62
Figure 16: Go To Market Strategy.......................................................................................................63
Figure 17: Value Assessment Frameworks ........................................................................................66
Figure 18: Product/Service Promotion Strategies ...............................................................................67
Figure 19: Precision Medicine: A Trigger to Unfold Innovative Business Model..................................68
Figure 20: Fixable Gaps in the Field of Precision Medicine ................................................................69
Figure 21: Estimated Ratios of Cost per Quality-Adjusted Life Year (QALY) Gained for Precision or
Personalized Medicine Tests..............................................................................................................71
Figure 22: Impact of Precision Medicine on Researchers, Manufacturers, and Consumers...............73
Figure 23: Opportunities and Challenges for Researchers, Providers, and Patients...........................74
Figure 1.1: Precision Medicine Approach ...........................................................................................76
Figure 1.2: Evolution of Precision Medicine Technology.....................................................................77
Figure 1.3: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored
Therapy ..............................................................................................................................................79
Figure 1.4: Precision Medicine: Remodeling Framework....................................................................81
Figure 1.5: Precision Medicine: Enabling Technologies......................................................................87
25. Global Precision Medicine Market
All rights reserved at BIS Research 25
Figure 1.6: Structured Big Data Reporting Benefits ............................................................................96
Figure 1.7: Generalized Process for the Microarray..........................................................................101
Figure 2.1: Market Dynamics of Global Precision Medicine Market..................................................102
Figure 2.2: Total Number of Genetic Products in Market ..................................................................105
Figure 2.3: Total Number of Genetic Products in Market ..................................................................106
Figure 2.4: % of Patients Whose Tumors Were Driven by Certain Genetic Mutations That Could Be
Targets for Specific Drugs ................................................................................................................108
Figure 2.5: Gene Therapy Products in Pipeline ................................................................................118
Figure 2.6: Sales Forecast for Gene Therapy Products (Yescarta and Kymriah), $ Million...............118
Figure 2.7: Precision Medicine Deals (2010-2017) ...........................................................................120
Figure 3.1: Competitive Landscape, January 2012-December 2018................................................121
Figure 3.2: Share of Key Developments and Strategies (January 2012-December 2018)................122
Figure 3.3: Joint Ventures, Partnerships, Agreements, and Collaborations Share by Companies
(January 2012-December 2018).......................................................................................................124
Figure 3.4: Product launches, Enhancements, and Upgradation Share by Companies (January 2012-
December 2018)...............................................................................................................................125
Figure 3.5: Product Approvals Share by Companies (January 2012-December 2018).....................126
Figure 3.6: Merger and Acquisitions Share by Companies (January 2012-December 2018)............127
Figure 3.7: Business Expansion Share by Companies (January 2012-December 2018)..................128
Figure 3.8: Other Developments Share by Companies (January 2012-December 2018).................129
Figure 3.9: Market Share Analysis by Applied Sciences, 2017.........................................................131
Figure 3.10: Market Share Analysis by Precision Diagnostics, 2017 ................................................133
Figure 3.11: Market Share Analysis by Precision Therapeutics, 2017..............................................135
Figure 3.12: Market Share Analysis by Digital Health and IT, 2017 ..................................................136
Figure 3.13: Porter’s Five Forces Analysis........................................................................................138
Figure 3.14: Definition of Suppliers and Buyers in the Precision Medicine Market............................139
Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2015-2028..........................................140
Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2015-2028..............................................141
Figure 3.17: Threat of New Entrant: Overall Impact, 2015-2028.......................................................142
Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028............................................143
Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2015-2028.........................................144
Figure 3.20: Supply Chain Analysis: Global Precision Medicine Market ...........................................145
Figure 4.1: Patent Analysis...............................................................................................................147
26. Global Precision Medicine Market
All rights reserved at BIS Research 26
Figure 4.2: Role of FDA in Advancing Precision Medicine................................................................149
Figure 5.1: Precision Medicine: The Ecosystem ...............................................................................157
Figure 5.2: Global Precision Medicine Market (by Ecosystem).........................................................158
Figure 5.3: Global Precision Medicine Market (by Ecosystem), 2017-2028......................................159
Figure 5.4: Global Precision Medicine Market (by Applied Sciences) ...............................................160
Figure 5.5: Global Precision Medicine Market (by Applied Sciences), 2017-2028 ............................160
Figure 5.6: Precision Medicine: Omics Sciences ..............................................................................161
Figure 5.7: Global Precision Medicine Applied Sciences Market (by Type), 2017-2028 ...................162
Figure 5.8: Precision Medicine: Genomics........................................................................................163
Figure 5.9: Global Precision Medicine Genomics Market, 2017-2028 ..............................................163
Figure 5.10: Global Precision Medicine Genomics Market (by Technology), 2017-2028..................164
Figure 5.11: Global Precision Medicine PCR Market, 2017-2028.....................................................165
Figure 5.12: Global Precision Medicine PCR Market (by Product Type), 2017-2028........................166
Figure 5.13: Global Precision Medicine PCR Market (by End User), 2017-2028..............................167
Figure 5.14: Global Precision Medicine PCR Market (by Region), 2017-2028..................................167
Figure 5.15: Evolution of Next-Generation Sequencing....................................................................169
Figure 5.16: Global Precision Medicine NGS Market, 2017-2028.....................................................170
Figure 5.17: Global Precision Medicine PM NGS Market (by Product Type), 2017-2028.................171
Figure 5.18: Global Precision Medicine NGS Market (by Technology), 2017-2028 ..........................172
Figure 5.19: Global Precision Medicine NGS Market (by End User), 2017-2028..............................173
Figure 5.20: Global Precision Medicine NGS Market (by Region), 2017-2028 .................................174
Figure 5.21: Global Precision Medicine Genome Editing Market, 2017-2028...................................175
Figure 5.22: Global Precision Medicine Genome Editing Market (by Product Type), 2017-2028......175
Figure 5.23: Global Precision Medicine Genome Editing Market (by End User), 2017-2028............176
Figure 5.24: Global Precision Medicine Genome Editing Market (by Region), 2017-2028................177
Figure 5.25: Global Precision Medicine Other Technologies Market, 2017-2028 .............................178
Figure 5.26: Global Precision Medicine Other Technologies Market (by Region), 2017-2028..........179
Figure 5.27: Clinical Applications of Pharmacogenomics Testing.....................................................180
Figure 5.28: Role of Biomarkers in Pharmacogenomics...................................................................181
Figure 5.29: Role of FDA In Pharmacogenomics..............................................................................184
Figure 5.30: Global Precision Medicine Pharmacogenomics Market, 2017-2028.............................185
Figure 5.31: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services),
2017-2028 ........................................................................................................................................186
27. Global Precision Medicine Market
All rights reserved at BIS Research 27
Figure 5.32: Global Precision Medicine Pharmacogenomics Market (by End User), 2017-2028......186
Figure 5.33: Global Precision Medicine Pharmacogenomics Market (by Region), 2017-2028..........187
Figure 5.34: Global Precision Medicine Other Applied Sciences Market, 2017-2028 .......................188
Figure 5.35: Precision Medicine: Diagnostics ...................................................................................189
Figure 5.36: Global Precision Medicine Market (by Precision Diagnostics).......................................190
Figure 5.37: Global Precision Medicine Market (by Precision Diagnostics), 2017-2028 ...................190
Figure 5.38: Global Precision Medicine Diagnostics Market (by Type), 2017-2028 ..........................191
Figure 5.39: General Workflow of a Molecular Diagnostic Assay......................................................193
Figure 5.40: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics) ..................193
Figure 5.41: Global Precision Medicine Molecular Diagnostics Market, 2017-2028..........................194
Figure 5.42: Global Precision Medicine Molecular Diagnostics Market (by Type), 2017-2028..........195
Figure 5.43: Benefits and Risks Associated with NIPT .....................................................................197
Figure 5.44: Global Precision Medicine NIPT Market, 2017-2028 ....................................................197
Figure 5.45: Global Precision Medicine NIPT Market (by Platform), 2017-2028...............................198
Figure 5.46: Global Precision Medicine NIPT Market (by Region), 2017-2028.................................199
Figure 5.47: Drug and Companion Diagnostics Development Process ............................................201
Figure 5.48: Benefits and Risks Associated with Companion Diagnostics........................................203
Figure 5.49: Global Precision Medicine Companion Diagnostics Market, 2017-2028.......................205
Figure 5.50: Global Precision Medicine Companion Diagnostics Market (by Technology), 2017-2028
..........................................................................................................................................................206
Figure 5.51: Global Precision Medicine Companion Diagnostics Market (by Indication), 2017-2028207
Figure 5.52: Global Precision Medicine Companion Diagnostics Market (by Region), 2017-2028...208
Figure 5.53: Clinical Applications of Liquid Biopsy............................................................................209
Figure 5.54: Global Precision Medicine Liquid Biopsy Market, 2017-2028 .......................................210
Figure 5.55: Global Precision Medicine Liquid Biopsy Market (by Indication), 2017-2028 ................211
Figure 5.56: Global Precision Medicine Liquid Biopsy Market (by Region), 2017-2028....................211
Figure 5.57: Global Precision Medicine Other Molecular Diagnostics Market, 2017-2028................213
Figure 5.58: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2017-2028
..........................................................................................................................................................214
Figure 5.59: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2017-2028
..........................................................................................................................................................215
Figure 5.60: Global Precision Medicine Medical Imaging Market, 2017-2028...................................217
Figure 5.61: Global Precision Medicine Medical Imaging Market (by Type), 2017-2028...................218
28. Global Precision Medicine Market
All rights reserved at BIS Research 28
Figure 5.62: Global Precision Medicine Medical Imaging Market (by Region), 2017-2028 ...............219
Figure 5.63: Global Precision Medicine Imaging Analytics Market, 2017-2028.................................220
Figure 5.64: Global Precision Medicine CADx Market, 2017-2028 ...................................................221
Figure 5.65: Global Precision Medicine Digital Health and Information Technology Market, 2017-2028
..........................................................................................................................................................223
Figure 5.66: Global Precision Medicine Digital Health and Information Technology Market (by Type),
2017-2028 ........................................................................................................................................224
Figure 5.67: Global Precision Medicine Digital Health and Information Technology Market (by End
User), 2017-2028..............................................................................................................................225
Figure 5.68: Global Precision Medicine Digital Health and Information Technology Market (by Region),
2017-2028 ........................................................................................................................................226
Figure 5.69: Global Precision Medicine CDSS Market, 2017-2028...................................................227
Figure 5.70: Big Data Attributes........................................................................................................229
Figure 5.71: Global Precision Medicine Big Data Analytics Market, 2017-2028................................230
Figure 5.72: Big Data Analytics: Key Benefits...................................................................................231
Figure 5.73: Global Precision Medicine IT Infrastructure Market, 2017-2028....................................232
Figure 5.74: Global Precision Medicine IT Infrastructure Market (by Type), 2017-2028....................233
Figure 5.75: Global Precision Medicine Genomics Informatics Market, 2017-2028..........................234
Figure 5.76: Global Precision Medicine Genomics Informatics Market (by Product Type), 2017-2028
..........................................................................................................................................................236
Figure 5.77: Global Precision Medicine In-Silico Informatics Market, 2017-2028..............................237
Figure 5.78: Global Precision Medicine Mobile Health Market, 2017-2028.......................................239
Figure 5.79: Global Precision Medicine Therapeutics Market, 2017-2028........................................241
Figure 5.80: Global Precision Medicine Therapeutics Market (by Type), 2017-2028........................242
Figure 5.81: Global Precision Medicine Clinical Trials Market, 2017-2028........................................243
Figure 5.82: Global Precision Medicine Clinical Trials Market (by Region), 2017-2028 ....................243
Figure 5.83: Types of Cell Therapy...................................................................................................245
Figure 5.84: Global Precision Medicine Cell Therapy Market, 2017-2028 ........................................245
Figure 5.85: Global Precision Medicine Cell Therapy Market (by Region), 2017-2028.....................246
Figure 5.86: Global Precision Medicine Drug Discovery and Research Market, 2017-2028.............248
Figure 5.87: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
..........................................................................................................................................................249
Figure 5.88: Types of Gene Therapy................................................................................................250
29. Global Precision Medicine Market
All rights reserved at BIS Research 29
Figure 5.89: Types of Gene Therapy................................................................................................251
Figure 5.90: Global Precision Medicine Gene Therapy Market, 2017-2028......................................251
Figure 5.91: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
..........................................................................................................................................................252
Figure 6.1: Therapeutic Areas in Precision Medicine........................................................................255
Figure 6.2: Global Precision Medicine Applications Market, 2017-2028 ...........................................256
Figure 6.3: Types of Cancer .............................................................................................................257
Figure 6.4: Global Precision Medicine Oncology Market, 2017-2028 ...............................................258
Figure 6.5: Global Precision Medicine Infectious Diseases Market, 2017-2028................................265
Figure 6.6: Number of Deaths by Top 18 Infectious Diseases, 2015................................................266
Figure 6.7: Global Precision Medicine Neurology/Physiatry Market, 2017-2028...............................268
Figure 6.8: Global Precision Medicine Cardiovascular Market, 2017-2028.......................................271
Figure 6.9: Global Precision Medicine Lifestyle and Endocrinology Market, 2017-2028...................273
Figure 6.10: Global Precision Medicine Gastroenterology Market, 2017-2028 .................................275
Figure 6.11: Global Precision Medicine Other Applications Market, 2017-2028................................277
Figure 7.1: Global Precision Medicine Market (by Region) ...............................................................280
Figure 7.2: Global Precision Medicine Market (by Region), 2017 and 2028 .....................................281
Figure 7.3: Global Precision Medicine Market (by Region), 2017-2028 ............................................281
Figure 7.4: North America Precision Medicine Market, 2017-2028...................................................282
Figure 7.5: North America Precision Medicine Market (by Country), 2017-2028...............................284
Figure 7.6: North America Precision Medicine Market (by Ecosystem), 2017-2028..........................285
Figure 7.7: The U.S. Precision Medicine Market, 2017-2028............................................................286
Figure 7.8: Canada Precision Medicine Market, 2017-2028 .............................................................291
Figure 7.9: Europe Precision Medicine Market, 2017-2028 ..............................................................294
Figure 7.10: Europe Precision Medicine Market (by Country), 2017-2028........................................296
Figure 7.11: Europe Precision Medicine Market (by Ecosystem), 2017-2028...................................297
Figure 7.12: Germany Precision Medicine Market, 2017-2028.........................................................298
Figure 7.13: France Precision Medicine Market, 2017-2028.............................................................301
Figure 7.14: Italy Precision Medicine Market, 2017-2028 .................................................................304
Figure 7.15: The U.K. Precision Medicine Market, 2017-2028..........................................................307
Figure 7.16: Spain Precision Medicine Market, 2017-2028...............................................................310
Figure 7.17: Rest-of-Europe Precision Medicine Market, 2017-2028................................................313
Figure 7.18: Asia-Pacific Precision Medicine Market, 2017-2028 .....................................................316
30. Global Precision Medicine Market
All rights reserved at BIS Research 30
Figure 7.19: Asia-Pacific Precision Medicine Market (by Country), 2017-2028.................................318
Figure 7.20: Asia-Pacific Precision Medicine Market (by Ecosystem), 2017-2028............................319
Figure 7.21: China Precision Medicine Market, 2017-2028...............................................................320
Figure 7.22: Japan Precision Medicine Market, 2017-2028..............................................................323
Figure 7.23: Australia Precision Medicine Market, 2017-2028..........................................................327
Figure 7.24: India Precision Medicine Market, 2017-2028................................................................330
Figure 7.25: Rest-of- Asia-Pacific Precision Medicine Market, 2017-2028........................................334
Figure 7.26: Latin America Precision Medicine Market, 2017-2028..................................................338
Figure 7.27: Latin America Precision Medicine Market (by Country), 2017-2028..............................339
Figure 7.28: Latin America Precision Medicine Market (by Ecosystem), 2017-2028.........................340
Figure 7.29: Brazil Precision Medicine Market, 2017-2028...............................................................341
Figure 7.30: Mexico Precision Medicine Market, 2017-2028.............................................................344
Figure 7.31: Rest-of-Latin America Precision Medicine Market, 2017-2028 .....................................345
Figure 7.32: Rest-of-the-World Precision Medicine Market, 2017-2028............................................347
Figure 7.33: Major Countries in the Middle East Precision Medicine Market.....................................349
Figure 8.1: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017..............................................355
Figure 8.2: Abbott Laboratories: Revenue (by Business Segment), 2015-2017 ...............................356
Figure 8.3: Abbott Laboratories: Revenue (by Region), 2015-2017..................................................357
Figure 8.4: Abbott Laboratories R&D Expenditure, 2015-2017.........................................................358
Figure 8.5: Amgen Inc.: Overall Financials, 2015-2017 ....................................................................363
Figure 8.6: Amgen Inc.: Revenue (by Region), 2015-2017...............................................................364
Figure 8.7: Amgen Inc. R&D Expenditure, 2014-2017......................................................................364
Figure 8.8: ANGLE plc: Overall Financials, 2015-2017.....................................................................367
Figure 8.9: ANGLE plc: Revenue (by Region), 2015-2017 ...............................................................368
Figure 8.10: ANGLE plc R&D Expenditure, 2014-2017 ....................................................................368
Figure 8.11: Astellas Pharma Inc.: Overall Financials, 2015-2017....................................................371
Figure 8.12: Astellas Pharma Inc.: Revenue (by Region), 2015-2017 ..............................................372
Figure 8.13: Astellas Pharma Inc. R&D Expenditure, 2015-2017 .....................................................372
Figure 8.14: Astra Zeneca PLC : Overall Financials, 2015-2017 ......................................................375
Figure 8.15: Astra Zeneca PLC: Revenue (by Business Segment), 2015-2017 ...............................376
Figure 8.16: Astra Zeneca PLC: Revenue (by Region), 2015-2017..................................................376
Figure 8.17: Astra Zeneca PLC R&D Expenditure, 2014-2017.........................................................377
Figure 8.18: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017............................................382
31. Global Precision Medicine Market
All rights reserved at BIS Research 31
Figure 8.19: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2015-2017 ....................383
Figure 8.20: Bio-Rad Laboratories, Inc: Revenue (by Region), 2015-2017.......................................383
Figure 8.21: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017.............................................384
Figure 8.22: bioMérieux SA.: Overall Financials, 2015-2017 ............................................................387
Figure 8.23: bioMérieux SA.: Revenue (by Business Segment), 2015-2017 ....................................388
Figure 8.24: bioMérieux SA.: Revenue (by Region), 2015-2017.......................................................388
Figure 8.25: bioMérieux SA. R&D Expenditure, 2014-2017..............................................................389
Figure 8.26: Bristol-Myers Squibb Company: Overall Financials, 2015-2017 ...................................392
Figure 8.27: Bristol-Myers Squibb Company: Revenue (by Region), 2015-2017..............................393
Figure 8.28: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017.....................................393
Figure 8.29: Canon Inc.: Overall Financials, 2015-2017...................................................................396
Figure 8.30: Canon Inc.: Revenue (by Segment), 2015-2017...........................................................396
Figure 8.31: Canon Inc.: Revenue (by Region), 2015-2017..............................................................397
Figure 8.32: Canon Inc.: R&D Expenditure, 2015-2017....................................................................398
Figure 8.33: Danaher Corporation: Overall Financials, 2015-2017...................................................403
Figure 8.34: Danaher Corporation: Revenue (by Business Segment), 2015-2017 ...........................403
Figure 8.35: Danaher Corporation: Revenue (by Region), 2015-2017..............................................404
Figure 8.36: Danaher Corporation R&D Expenditure, 2014-2017.....................................................405
Figure 8.37: Eli Lilly and Company Limited: Overall Financials, 2015-2017......................................408
Figure 8.38: Eli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017..............409
Figure 8.39: Eli Lilly and Company Limited: Revenue (by Region), 2015-2017 ................................410
Figure 8.40: Eli Lilly and Company Limited R&D Expenditure, 2014-2017 .......................................410
Figure 8.41: F.Hoffman-LA Roche AG: Overall Financials, 2015-2017.............................................415
Figure 8.42: Elli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017.............416
Figure 8.43: F.Hoffman-LA Roche AG : Revenue (by Region), 2015-2017 .....................................417
Figure 8.44: F.Hoffman-LA Roche AG R&D Expenditure, 2014-2017 .............................................417
Figure 8.45: GE Corporation Limited: Overall Financials, 2015-2017 ...............................................420
Figure 8.46: GE Corporation: Revenue (by Business Segment), 2015-2017....................................421
Figure 8.47: GE Corporation: Revenue (by Region), 2015-2017 ......................................................422
Figure 8.48: GE Corporation R&D Expenditure, 2014-2017 .............................................................422
Figure 8.49: Gilead Sciences, Inc.: Overall Financials, 2015-2017...................................................425
Figure 8.50: Gilead Sciences, Inc.: Revenue (by Business Segment), 2015-2017...........................426
Figure 8.51: Gilead Sciences, Inc.: Revenue (by Region), 2015-2017..............................................426
32. Global Precision Medicine Market
All rights reserved at BIS Research 32
Figure 8.52: Gilead Sciences, Inc. R&D Expenditure, 2014-2017....................................................427
Figure 8.53: GlaxoSmithKline Plc: Overall Financials, 2015-2017....................................................430
Figure 8.54: GlaxoSmithKline Plc: Revenue (by Business Segment), 2015-2017 ............................431
Figure 8.55: GlaxoSmithKline Plc: Revenue (by Region), 2015-2017...............................................431
Figure 8.56: GlaxoSmithKline Plc R&D Expenditure, 2014-2017......................................................432
Figure 8.57: IBM Corporation: Overall Financials, 2015-2017 ..........................................................435
Figure 8.58: IBM Corporation: Revenue (by Business Segment), 2015-2017...................................436
Figure 8.59: IBM Corporation: Revenue (by Region), 2015-2017.....................................................437
Figure 8.60: IBM Corporation R&D Expenditure, 2014-2017............................................................437
Figure 8.61: Illumina, Inc.: Overall Financials, 2015-2017 ................................................................440
Figure 8.62: Illumina, Inc.: Revenue (by Business Segment), 2015-2017.........................................441
Figure 8.63: Illumina, Inc.: Revenue (by Region), 2015-2017...........................................................441
Figure 8.64: Illumina, Inc. R&D Expenditure, 2014-2017..................................................................442
Figure 8.65: Johnson and Johnson: Overall Financials, 2015-2017 .................................................447
Figure 8.66: Johnson and Johnson: Revenue (by Business Segment), 2015-2017..........................448
Figure 8.67: Johnson and Johnson Revenue (by Region), 2015-2017.............................................449
Figure 8.68: Johnson and Johnson R&D Expenditure, 2014-2017...................................................449
Figure 8.69: Konica Minolta, Inc.: Overall Financials, 2015-2017 .....................................................452
Figure 8.70: Konica Minolta, Inc.: Revenue (by Segment), 2015-2017.............................................452
Figure 8.71: Konica Minolta, Inc.: Revenue (by Region), 2015-2017................................................453
Figure 8.72: Konica Minolta, Inc.: R&D Expenditure, 2015-2017......................................................454
Figure 8.73: Lab Corporation of America: Overall Financials, 2015-2017.........................................457
Figure 8.74: Lab Corporation of America: Revenue (by Business Segment), 2015-2017.................458
Figure 8.75: Lab Corporation of America: Revenue (by Region), 2015-2017 ...................................458
Figure 8.76: MDx Health, Inc.: Overall Financials, 2015-2017..........................................................461
Figure 8.77: MDx Health, Inc. R&D Expenditure, 2014-2017............................................................462
Figure 8.78: Merck & Co., Inc.: Overall Financials, 2015-2017.........................................................468
Figure 8.79: Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017 .................................469
Figure 8.80: Merck & Co., Inc.: Revenue (by Region), 2015-2017....................................................469
Figure 8.81: Merck & Co., Inc. R&D Expenditure, 2015-2017..........................................................470
Figure 8.82: Myriad Genetics, Inc.: Overall Financials, 2015-2017...................................................473
Figure 8.83: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017...........................474
Figure 8.84: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017..............................................475